Author

Scott J. Sherman

University of Arizona

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:rat· 5 Approach:experimental assay· 4 Assay:behavioral assay· 2 Research Focus:host-pathogen & immune response· 2 Approach:statistical model· 1

Frequent Co-Authors

Torsten FalkiD· 5 shared Mitchell J. BartlettiD· 3 shared Carolyn J. StoperaiD· 2 shared Jasmine R. Meredith· 2 shared Mitchell J. Bartlett· 2 shared Raveena Parmar· 2 shared Sansita Singh· 2 shared Andrew J. FloresiD· 1 shared

Activity by Year

2023-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersNeuroscience

Torsten FalkORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Dyskinesia induced by a dopamine 2 receptor-like agonist, but not a dopamine 1 receptor-like agonist, is blocked by sub-anesthetic ketamine

Raveena Parmar, Jasmine R. Meredith, Mitchell J. Bartlett, Emma G. E. Smith, Jeanelle M. Castro, Scott J. Sherman, Gaurav Chattree, Kathy Steece-Collier, Torsten Falk

This study shows that sub-anesthetic ketamine reduces dyskinesia caused by D2R-like receptor agonists but not D1R-like receptor agonists in L-DOPA-primed rats.

bioRxiv · Nov 3, 2026 · PreprintNeuroscience

The anti-dyskinetic and the anti-parkinsonian effects of sub-anesthetic ketamine are also present in female preclinical models

Raveena Parmar, Mitchell J. Bartlett, Jasmine R. Meredith, Sansita Singh, Sydney Ragsdale, Scott J. Sherman, Torsten Falk

This study shows that sub-anesthetic ketamine reduces dyskinesia and improves motor function in female preclinical models of Parkinson's disease and L-DOPA-induced dyskinesia.

bioRxiv · Nov 3, 2026 · PreprintNeuroscience

Neuroprotective activity of sub-anesthetic ketamine in a preclinical model of Parkinson's disease is not blocked by antagonizing brain-derived neurotrophic factor signaling

Carolyn J. Stopera, Mitchell J. Bartlett, Kelsey Bernard, Rachel Conklin, Sansita Singh, Jennifer Beischel Frye, Lalitha Madhavan, Kristian P. Doyle, Scott J. Sherman, Kathy Steece‐Collier, Torsten Falk

This study shows that low-dose ketamine protects against Parkinson's-like motor deficits in rats without relying on BDNF-TrkB signaling.

bioRxiv · Oct 29, 2026 · PreprintNeuroscience

Differential effects of statins on the anti-dyskinetic activity of sub-anesthetic ketamine

Mitchell J. Bartlett, Carolyn J. Stopera, Stephen L. Cowen, Scott J. Sherman, Torsten Falk

This study examines how different statins affect the anti-dyskinetic effects of sub-anesthetic ketamine in a rat model of L-DOPA-induced dyskinesia.

Neuroscience Letters · Jan 4, 2025Peer-reviewedNeuroscience

Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion

Andrew J. Flores, Mitchell J. Bartlett, Blake T. Seaton, Grace Samtani, Morgan R. Sexauer, Nathan C. Weintraub, James R. Siegenthaler, Dong Lu, Michael L. Heien, Frank Porreca, Scott J. Sherman, Torsten Falk

This study shows that blocking kappa opioid receptors increases the rate of L-DOPA-induced dyskinesia development in a rat Parkinson's model but does not affect motor symptoms or tonic dopamine levels.

Brain Research · Dec 1, 2023Peer-reviewedNeuroscience